Glutamate receptor metabotropic 7 (GRM7) gene polymorphisms in mood disorders and attention deficit hyperactive disorder.
Adult
Alleles
Attention Deficit Disorder with Hyperactivity
/ genetics
Bipolar Disorder
/ genetics
Depressive Disorder, Major
/ genetics
Female
Gene Frequency
Genes, Dominant
Genes, Recessive
Genotype
Haplotypes
Humans
Male
Middle Aged
Polymorphism, Single Nucleotide
Receptors, Metabotropic Glutamate
/ genetics
Attention deficit hyperactive disorder
Bipolar I disorder
Bipolar II disorder
Glutamate receptor metabotropic 7
Major depressive disorder
Journal
Neurochemistry international
ISSN: 1872-9754
Titre abrégé: Neurochem Int
Pays: England
ID NLM: 8006959
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
03
01
2019
revised:
13
05
2019
accepted:
03
06
2019
pubmed:
7
6
2019
medline:
12
5
2020
entrez:
7
6
2019
Statut:
ppublish
Résumé
L-glutamate is the chief excitatory neurotransmitter in the central nervous system (CNS) which activates metabotropic receptors including the metabotropic glutamate receptor GRM7. Single nucleotide polymorphisms (SNPs) within GRM7 gene have been associated with several psychiatric conditions. In the present study, we assessed association between two GRM7 SNPs (rs6782011 and rs779867) and two neuropsychiatric disorders including attention deficit hyperactive disorder (ADHD) and mood disorders. There were no significant differences in genotype, allele and haplotypes frequencies of the rs6782011 and rs779867 between bipolar disorder 1 (BPD1) patients and controls. The CC genotype of the rs6782011 was significantly associated with BPD2 in recessive model (OR (95% CI) = 1.78 (1.09-2.91), adjusted P value = 0.04) and with ADHD in dominant and co-dominant models (OR (95% CI) = 1.98 (1.11-3.53), adjusted P value = 0.04; OR (95% CI) = 2.27 (1.23-4.17), adjusted P value = 0.04 respectively). The C G haplotype (rs6782011 and rs779867 respectively) was more prevalent among both BPD2 patients (OR (95%CI) = 2.03 (1.36-3.01), adjusted P value = 0.002) and MDD patients (OR (95%CI) = 2.08 (1.37-3.16), adjusted P value = 0.002) compared with controls. The current study provides further evidences for participation of GRM7 variants in conferring risk of neuropsychiatric disorders.
Identifiants
pubmed: 31170425
pii: S0197-0186(19)30016-6
doi: 10.1016/j.neuint.2019.104483
pii:
doi:
Substances chimiques
Receptors, Metabotropic Glutamate
0
metabotropic glutamate receptor 7
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
104483Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.